0001140361-25-005053.txt : 20250218 0001140361-25-005053.hdr.sgml : 20250218 20250218210026 ACCESSION NUMBER: 0001140361-25-005053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250213 FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Rakhi CENTRAL INDEX KEY: 0001856296 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 25636973 MAIL ADDRESS: STREET 1: C/O NEUROPACE INC STREET 2: 455 N BERNARDO AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4.xml FORM 4 X0508 4 2025-02-13 0001635088 Roivant Sciences Ltd. ROIV 0001856296 Kumar Rakhi C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true Chief Accounting Officer false Common Shares 2025-02-13 4 M 0 187500 3.85 A 390764 D Common Shares 2025-02-13 4 S 0 227500 10.43 D 163264 D Stock Option (Right to Buy) 3.85 2025-02-13 4 M 0 187500 0 D 2032-04-19 Common Stock 187500 312500 D The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Rakhi Kumar 2025-02-18